Skip to content

Anticipation and Detection of Heart Failure Decompensation With Automatic Treatment of Informations

Anticipation and Detection of Heart Failure Decompensation With Automatic Treatment of Informations Derived From Non Intrusive Sensors and Devices

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02411279
Acronym
e-INCA
Enrollment
20
Registered
2015-04-08
Start date
2015-06-30
Completion date
2017-09-30
Last updated
2017-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Heart failure, telemonitoring, intrusive sensors, intrusive devices, Heart failure stage II, Heart failure stage III, heart disease

Brief summary

Heart failure (HF) is a serious chronic disease with frequent readmissions, some of which can be prevented by early action. The management of HF is complex: long, often difficult and costly. In France, nearly one million people suffer from HF and 120,000 new cases are diagnosed every year. With the aging population, this number will continue to evolve and become a real public health problem. Within 10 to 20 years ahead, WHO projects that heart failure in either the 3 most common diseases in industrialized countries. The objective of the project is to test an intelligent platform for monitoring at home, using non-intrusive sensors, patients with heart failure, particularly those with stage II and III NYHA. It will assist the medical automating the processing of information from these sensors to detect and report an early stage risk situations. Patient monitoring, by a system of telemedicine tools associated with motivation and education helps significantly reduce the number of days of hospitalization becomes important when the patient is hospitalized for acute HF.

Interventions

OTHEREquiped group with telemedicine systems

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Population with heart failure stage II and III

Exclusion criteria

* Population whose age is less than 18 years

Design outcomes

Primary

MeasureTime frame
Anticipation and detection of heart failure with automatic treatment of information derived from non intrusive sensors and devicespatient's medical data will be controlled remotely by health professional for the duration of hospital stay, up to 1 year]

Countries

France

Contacts

Primary ContactANDRES Emmanuel, MD, PhD
Emmanuel.ANDRES@chru-strasbourg.fr333 8811 5066

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026